Core Viewpoint - Zydus Lifesciences and its U.S. unit will pay $120 million to Astellas Pharma to settle a patent dispute regarding the bladder disorder drug Mirabegron, allowing Zydus to continue marketing its generic version in the U.S. [1][2] Group 1 - The settlement includes a pre-paid per-unit licensing fee on sales of Zydus's generic Mirabegron in the U.S. until September 2027 [1] - Following the announcement, shares of Zydus increased by as much as 1.3% [2] - The deal comes shortly after Lupin, a local competitor, settled a similar dispute with Astellas for $90 million [2] Group 2 - Analysts from Citi indicated that the settlement could delay the entry of other generic competitors in the U.S. market, potentially providing Zydus and Lupin with a period of limited competition [3]

Core Viewpoint - Lupin has reached a Settlement and License Agreement with Astellas Pharma regarding a patent infringement dispute over the product 'Mirabegron', allowing Lupin to continue selling its version of the drug while resolving ongoing litigation [1][2]. Group 1: Financial Terms of the Settlement - Lupin will pay Astellas a total of $90 million, which includes a Prepaid Option Payment of $75 million and a Prepaid Per Unit License Fee for each unit of Lupin's product sold until September 2027 [1]. Group 2: Product Information - The product in question, Mirabegron, is used to treat overactive bladder symptoms, including urge urinary incontinence, urgency, and urinary frequency, and is marketed by Astellas under the Myrbetriq trademark [2]. Group 3: Ongoing Litigation - Astellas has indicated that litigation involving Myrbetriq with other companies is still ongoing and is assessing the potential financial impact of these developments for the fiscal year ending March 31, 2026 [3].

Core Viewpoint - Lupin has reached a settlement with Astellas Pharma to resolve a patent infringement dispute regarding its Mirabegron product, agreeing to pay a total of $90 million, which includes a prepaid option payment of $75 million and a prepaid per-unit license fee for each unit sold until September 2027 [1][5]. Group 1: Settlement Details - The settlement amount totals $90 million, comprising a prepaid option payment of $75 million and additional fees based on product sales [1][5]. - The financial and commercial terms of the settlement remain confidential [2][5]. - The agreement resolves pending litigation with Astellas, allowing Lupin to continue marketing and selling Mirabegron in the U.S., thus eliminating a significant legal hurdle [2][5]. Group 2: Impact on Business Operations - The settlement provides closure to the patent dispute initially disclosed by Lupin in April 2025 [4][5]. - This resolution enhances visibility on the near-term commercial trajectory of the Mirabegron product [4][5].

Core Viewpoint - Indian drugmaker Lupin has settled a patent infringement dispute with Japan's Astellas Pharma regarding the bladder disorder drug Mirabegron, enabling Lupin to continue selling the product [1] Company Summary - Lupin has reached a settlement that allows it to maintain its market presence for Mirabegron, a drug used to treat bladder disorders [1] - The resolution of this dispute is significant for Lupin as it secures its ability to sell a key product without legal hindrances [1] Industry Summary - The settlement highlights ongoing patent disputes within the pharmaceutical industry, particularly concerning generic drug manufacturers and brand-name companies [1] - The outcome of such disputes can influence market dynamics and competition in the bladder disorder treatment segment [1]